Receptor Life Sciences
Specializing in nervous system disorders and drug-delivery technologies, while also offering oral cannabinoid products to address unmet medical needs.
Specializing in nervous system disorders and drug-delivery technologies, while also offering oral cannabinoid products to address unmet medical needs.
Receptor Life Sciences is a biotechnology startup founded in 2015, specializing in nervous system disorders and drug-delivery technologies. With a focus on addressing unmet medical needs, the company also offers oral cannabinoid products. Their latest achievement includes securing a noteworthy $9.70M Series A investment on 07 April 2022 from Granite Point Capital. Receptor Life Sciences is determined to revolutionize the treatment of nervous system disorders and aims to make significant strides in the commercialization of therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $9.70M | 1 |
|
07 Apr 2022 |
| Series A | $29.00M | - | 29 Oct 2018 | |
| Debt Financing | $7.57M | - | 04 Oct 2018 |
No recent news or press coverage available for Receptor Life Sciences.
We care about your data, and we'd love to use cookies make your experience better.
